M. C. AVENDAÑO
424
7. Yao, F.; MacKenzie, R. G., (2010) “Obesity Drug Update: The Lost Decade?” Pharmaceuticals, 3,
3494-‐3521.
8. Nören-‐Müller, A.; Reis-‐Corrêa, I.; Prinz, H.; Rosenbaum, C.; Saxena, K.;
Schwalbe, H. J.;
Vestweber, D.; Cagna, G.; Schunk, S.; Schwarz, O.; Schiewe, H.; Waldmann, H., (2006) “Discovery
of protein phosphatase inhibitor classes by biology-‐oriented síntesis”, Proc. Natl. Acad. Sci. U S A.,
103,10606-‐10611.
9. Lachance, H.; Wetzel, S.; Kumar, K.; Waldmann, H., (2012) “Charting, Navigating, and Populating
Natural Product Chemical Space for Drug Discovery”, J. Med. Chem., 55, 5989-‐6001.
10. Vasilevich, N. I.; Kombarov, R. V.; Genis, D. V.; Kirpichenok, M. A., (2012) “Lessons from Natural
Products Chemistry Can Offer Novel Approaches for Synthetic Chemistry in Drug Discovery”, J.
Med. Chem., 55, 7003-‐7009.
11. Schreiber, S. L., (2000) “Target-‐oriented and diversity-‐oriented organic synthesis in drug
discovery”, Science, 287, 1964-‐1969.
12. Nielsen, T. E.; Schreiber, S. L., (2008) “Towards the Optimal Screening Collection: A Synthesis
Strategy”, Angew. Chem. Int. Ed. Engl., 47, 48-‐56.
13. Baniecki, M. L.; Wirth, D. F.; Clardy, J., (2007) “High-‐throughput Plasmodium falciparum growth
assay for malaria drug discovery”, Antimicrob. Agents Chemother., 51, 716-‐723.
